A multi-center, open-label clinical trial to determine the safety of ABX-EGF as continued treatment for patients who have benefited from and tolerated prior ABX-EGF treatment

Trial Profile

A multi-center, open-label clinical trial to determine the safety of ABX-EGF as continued treatment for patients who have benefited from and tolerated prior ABX-EGF treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2008

At a glance

  • Drugs Panitumumab (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 26 Jul 2008 The expected completion date for this trial is now .
    • 20 Jul 2008 Actual patient number is now 31 as reported by ClinicalTrials.gov.
    • 20 Jul 2008 Trial phase changed from I to II as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top